Angiogenesis in Chronic Lymphocytic Leukemia

ISSN: 2211-5536 (Online)
ISSN: 2211-5528 (Print)


Volume 3, 4 Issues, 2014


Download PDF Flyer




Current Angiogenesis

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Guo-Chang Fan, PHD
Dept. of Pharmacology and Cell Biophysics
University of Cincinnati College of Medicine
231 Albert Sabin Way
Cincinnati, OH 45267
USA
Email: FANGG@ucmail.uc.edu

View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Angiogenesis in Chronic Lymphocytic Leukemia

Author(s): Sotirios Sachanas, Maria K. Angelopoulou, Pinelopi Korkolopoulou, Christina Kalpadakis, Pantelis Tsirkinidis, Maria Moschogiannis, Xanthi Yiakoumis, Aglaia Dimitrakopoulou, Theodoros P. Vassilakopoulos and Gerassimos A. Pangalis

Affiliation: Athens Medical Center, Phychikon Branch, Andersen 1, 11525, Athens, Greece.

Abstract

Data concerning angiogenesis in chronic lymphocytic leukaemia (CLL) indicate that CLL patients are characterized by various abnormalities in the angiogenic profile including increased microvessel density in lymph nodes and in bone marrow and increased levels of certain pro-angiogenic vascular growth factors. Vascular endothelial growth factor (VEGF) and its receptors, basic fibrobast growth factor (bFGF) and matrix metalloproteinases(MMPs) were found to be highly expressed in CLL patients while there was no difference in angiogenin expression between CLL patients and healthy individuals. VEGF is implicated in CLL pathogenesis through various mechanisms. Enhanced angiogenesis in CLL has been associated in several reports with disease characteristics and patients’ survival. Various anti-angiogenic agents targeting angiogenesis related pathways such as immunomodulatory drugs and receptor tyrosine kinase inhibitors have already been entered in clinical trials. Among them lenalidomide is the most promising antiangiogenic drug showing a significant efficacy in relapsed/refractory CLL patients.

Keywords: Angiogenesis, antiangiogenic drugs, chronic lymphocytic leukemia, vascular growth factors.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 2
Issue Number: 2
First Page: 96
Last Page: 103
Page Count: 8
DOI: 10.2174/22115528113026660011
Advertisement

Related Journals



Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science